Advertisement

Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study

Published:April 07, 2021DOI:https://doi.org/10.1016/j.ejim.2021.03.029

      Abstract

      Background

      . Patients with concomitant atrial fibrillation (AF) and acute coronary syndromes (ACS) do not seem to receive proper antithrombotic therapies and present high rates of adverse clinical events.

      Methods

      . We analyzed the follow-up data of the prospective, nationwide MATADOR-PCI registry. We assessed the use of antithrombotic strategies and the incidence of major adverse cardiovascular events (MACE) and net adverse clinical events (NACE) at 6 months, in patients with new-onset or pre-existing AF admitted for ACS and treated with percutaneous coronary intervention (PCI).

      Results

      . Out of the 588 patients enrolled in the registry and discharged alive (287 with pre-existing and 301 with new-onset AF), data at 6 months were obtained for 579 (98.5%) patients. Compared to hospital discharge, the rate of triple antithrombotic therapy was significantly reduced (from 76.4% to 23.6% and from 53.8% to 23.6%; both p<0.0001) while dual antithrombotic therapy (DAT) increased (from 11.8% to 56.3% and from 5.8% to 30.9%; both p<0.0001) at follow-up, in patients with pre-existing and new-onset AF, respectively. Among patients with a class IA indication to receive oral anticoagulation therapy (OAT), it was prescribed in 91% and 88% of patients with pre-existing and 64% and 62% of new-onset AF, at discharge and follow-up, respectively. At 6 months from discharge the overall rate of MACE was 8.4% and 7.6% (p=0.75), while NACE occurred in 10.8% vs 10.0% (p=0.74) of patients with pre-existing or new-onset AF, respectively.

      Conclusions

      . At follow-up, DAT was the most used antithrombotic strategy for both patients with pre-existing and new-onset AF with concomitant ACS. These two groups of patients presented comparable rates of MACE and NACE at 6 months.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • De Luca L.
        • Casella G.
        • Rubboli A.
        • et al.
        Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation.
        Int J Cardiol. 2017; 248: 369-375
        • Guimaraes P.O.
        • Zakroysky P.
        • Goyal A.
        • Lopes R.D.
        • Kaltenbach L.A.
        • Wang T.Y.
        Usefulness of antithrombotic therapy in patients with atrial fibrillation and acute myocardial infarction.
        Am J Cardiol. 2019; 123: 12-18
        • Erez A.
        • Goldenberg I.
        • Sabbag A.
        • et al.
        Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome: real-world data from the Acute Coronary Syndrome Israeli Survey (ACSIS).
        Clin Cardiol. 2017; 40 (2000-2013): 275-280
        • Rene A.G.
        • Genereux P.
        • Ezekowitz M.
        • et al.
        Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the horizons-ami [harmonizing outcomes with revascularization and stents in acute myocardial infarction] trial).
        Am J Cardiol. 2014; 113: 236-242
        • Podolecki T.
        • Lenarczyk R.
        • Kowalczyk J.
        • et al.
        Significance of atrial fibrillation complicating st-segment elevation myocardial infarction.
        Am J Cardiol. 2017; 120: 517-521
        • Lopes R.D.
        • White J.A.
        • Atar D.
        • et al.
        Incidence, treatment, and outcomes of atrial fibrillation complicating non-st-segment elevation acute coronary syndromes.
        Int J Cardiol. 2013; 168: 2510-2517
        • Zusman O.
        • Amit G.
        • Gilutz H.
        • et al.
        The significance of new onset atrial fibrillation complicating acute myocardial infarction.
        Clin Res Cardiol. 2012; 101: 17-22
        • Hofer F.
        • Kazem N.
        • Hammer A.
        • et al.
        Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies.
        Eur Heart J Cardiovasc Pharmac. 2020; (in press)https://doi.org/10.1093/ehjcvp/pvaa027
        • Lee J.H.
        • Kim S.
        • Lee W.
        • et al.
        New-onset paroxysmal atrial fibrillation in acute myocardial infarction: increased risk of stroke.
        BMJ Open. 2020; 10e039600
        • Wi J.
        • Shin D.H.
        • Kim J.S.
        • et al.
        Transient new-onset atrial fibrillation is associated with poor clinical outcomes in patients with acute myocardial infarction.
        Circ J. 2016; 80: 1615-1623
        • Vitolo M.
        • Javed S.
        • Capodanno D.
        • Rubboli A.
        • Boriani G.
        • Lip G.Y.H.
        Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis.
        Expert Rev Cardiovasc Ther. 2020; 18: 587-600
        • Hindricks G.
        • Potpara T.
        • Dagres N.
        • et al.
        ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2020; (Online ahead of print)https://doi.org/10.1093/eurheartj/ehaa612
        • De Luca L.
        • Rubboli A.
        • Bolognese L.
        • et al.
        Antithrombotic management of patients with acute coronary syndromes and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study.
        BMJ Open. 2020; 10e041044
        • De Luca L.
        • Bolognese L.
        • Rubboli A.
        • et al.
        Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: data from the nationwide MATADOR-PCI registry.
        Eur Heart J Cardiovasc Pharmacother. 2020; (pvaa088)https://doi.org/10.1093/ehjcvp/pvaa088
        • Thygesen K.
        • Alpert J.S.
        • Jaffe A.S.
        • Simoons M.L.
        • Chaitman B.R.
        • White H.D.
        Joint ESC/ACCF/AHA/WHF task force for universal definition of myocardial Infarction. Third universal definition of myocardial infarction.
        J Am Coll Cardiol. 2012; 60: 1581-1598
        • Mehran R.
        • Rao S.V.
        • Bhatt D.L.
        • et al.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
        Circulation. 2011; 123: 2736-2747
        • Zeymer U.
        • Annemans L.
        • Danchin N.
        • et al.
        Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR registry.
        Eur Heart J Acute Cardiovasc Care. 2019; 8: 121-129
        • January C.T.
        • Wann L.S.
        • Calkins H.
        • et al.
        AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons.
        Circulation. 2019; 140 (2019): e125-e151
        • Gulizia M.M.
        • Cemin R.
        • Colivicchi F.
        • et al.
        BLITZ-AF investigators. management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study.
        Europace. 2019; 21: 230-238
        • Faxén J.
        • Jernberg T.
        • Hollenberg J.
        • et al.
        Incidence and predictors of out-of-hospital cardiac arrest within 90 days after myocardial infarction.
        J Am Coll Cardiol. 2020; 76: 2926-2936
        • Fukunami M.
        Transient atrial fibrillation during acute myocardial infarction is a predictor of poor outcomes.
        Circ J. 2016; 80: 1534-1536
        • Wang J.
        • Yang Y.M.
        • Zhu J.
        Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome.
        Herz. 2015; 40 (Suppl): 18-26
        • Lip G.Y.H.
        • Collet J.
        • Haude M.
        • et al.
        Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).
        Europace. 2018; 21 (2019): 192-193
        • Gargiulo G.
        • Goette A.
        • Tijssen J.
        • et al.
        Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
        Eur Heart J. 2019; 40: 3757-3767
        • Khan S.U.
        • Osman M.
        • Khan M.U.
        • et al.
        Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention: a systematic review and meta-analysis.
        Ann Intern Med. 2020; 172: 474-483
        • Lopes R.D.
        • Hong H.
        • Harskamp R.E.
        • Bhatt D.L.
        • et al.
        Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis.
        JAMA Cardiol. 2020; 5: 582-589
        • Collet J.P.
        • Thiele H.
        • Barbato E.
        • et al.
        ESC Scientific Document Group. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
        Eur Heart J. 2020; (Online ahead of print)https://doi.org/10.1093/eurheartj/ehaa575